AI Rewiring Big Pharma Drug Development

Eli Lilly and Novo Nordisk are leveraging artificial intelligence (AI) to accelerate drug development, particularly for their dominant GLP-1 medications. This strategic integration of AI spans various stages of the research and production pipeline, aiming to significantly reduce the time it takes for new medicines to reach the market. Eli Lilly's substantial $2.75 billion partnership highlights the growing investment in AI-driven pharmaceutical innovation, signaling a major shift in how the industry approaches the creation of life-changing treatments.